2020-12-24 08:35:17 GMT2020-12-24 16:35:17(Beijing Time) Xinhua English
SAO PAULO, Dec. 23 (Xinhua) Brazil s state-run Butantan Institute on Wednesday announced that the CoronaVac vaccine developed by the private Chinese laboratory Sinovac Life Science achieved the levels of efficacy against the coronavirus required by the World Health Organization (WHO) in trials with 13,000 Brazilian volunteers. The data corroborate that it is the safest vaccine on the market and we achieved the superiority in efficacy required by the WHO and Brazil s Health Regulatory Agency (Anvisa), Dimas Covas, director of the institute, said at a press conference.
The level of efficacy required by the WHO is greater than 50 percent, he said.
Brazil s Butantan Institute announces efficacy of China s CoronaVac vaccine on Brazilian volunteers - Xinhua xinhuanet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from xinhuanet.com Daily Mail and Mail on Sunday newspapers.
Through the Secretary of Health Surveillance, Arnaldo Correia de Medeiros, the Ministry of Health said it predicts 258,4 million units of vaccines against Covid-19 in the country as of January. These are immunizers from various pharmaceutical companies in an effort to cover the entire demand for the start of vaccination. While the Brazil still discusses the start of immunization, other countries are already vaccinating.
Thus, according to Medeiros, the intention is for the country to have access to 42 million units of the vaccine from the Covax Facility consortium, as well as to 100,4 million of the pharmaceutical vaccine. AstraZeneca, which is being developed in partnership with Oxford University. About this immunizer, Fundação Oswaldo Cruz (Fiocruz), which will manufacture the vaccine here in Brazil, says that the plan is to produce one million units in the first week of February. Soon after, the Foundation wants to establish a production of 700 thousand units a day.